Navigation Links
Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
Date:11/12/2013

hyperlipidemia who cannot tolerate statins and as a stand-alone treatment, respectively.

Data presented on evolocumab will include:

  • Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-Term Administration of AMG 145 Versus Standard of Care in 1104 Patients: 52-Week Results from the OSLER Study  
    CS.03, Clinical Science: Special Reports, Tuesday, Nov. 19, 4:51 - 5:01 p.m. CST (Ballrooms C1 & C2)
  • Efficacy and Safety of Long-Term Treatment with AMG 145 Monotherapy
    Abstract 12191, Abstract Poster Session, Tuesday, Nov. 19, 3 - 4:30 p.m. CST (Hall F, Core 2, Poster Board: 2010)
  • Efficacy and Tolerability of Long-Term Treatment With AMG 145 in Patients With Statin Intolerance
    Abstract 12621, Abstract Poster Session, Tuesday, Nov. 19, 3 - 4:30 p.m. CST (Hall F, Core 2, Poster Board: 2009)

Amgen will also host a webcast investor meeting at AHA on Tuesday, Nov. 19, at 7 p.m. CST. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.

Live audio of the investor meeting will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the ev
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
2. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
4. Amgen And Servier Complete Product Collaboration Transaction
5. Amgen Announces 2013 Third Quarter Dividend
6. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
7. Amgen And Servier Announce Product Collaboration
8. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
9. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
10. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
11. Amgen Announces 2013 Second Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)...  Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage ... therapeutics including high value and difficult to manufacture ... announced underwritten public offering of 6,750,000 shares of ... of $15.50 per share. This includes the exercise ... to purchase up to 750,000 additional shares of ...
(Date:4/30/2015)... Available in select spas in ... , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield Cream provides ... battling the weakening threat of inflammaging, aging directly ... with star ingredient GLYCOSEA, a complex of restructuring ... of soothing minerals and trace elements. GLYCOSEA works ...
(Date:4/29/2015)... BALTIMORE, Maryland, USA (PRWEB) April 29, 2015 ... photonics, optical sensing, and imaging on the East Coast, ... government program managers, researchers, applications developers, and industry suppliers ... sensing and imaging for multiple applications. , The event ... security, and commercial and scientific sensing and imaging -- ...
(Date:4/29/2015)... (PRWEB) April 29, 2015 The leading ... announce that its regenerative stem cell therapy has processed ... 2002, seeking to discover a successful treatment for horses ... In 2003 VetStem signed a worldwide exclusive license for ... and the first horse was treated in January 2004. ...
Breaking Biology Technology:Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2
... Dec. 29, 2010 Reportlinker.com announces that ... in its catalogue: Molecular Diagnostics Markets ... The technologies that constitute molecular ... situ hybridization (FISH), second-generation biochips and microfluidics, ...
... DIEGO, Dec. 28, 2010 Cardium Therapeutics (NYSE Amex: ... the Company,s Matrix Phase 2b clinical study has been ... and Regeneration and provided an update on plans ... dressing.   (Logo:   http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO ) ...
... 2010 An international team of researchers featuring Texas ... that gives a new spin to semiconductor nanoelectronics and ... developed an electrically controllable device whose functionality is based ... a 20-year scientific quest involving many international researchers and ...
Cached Biology Technology:Reportlinker Adds Molecular Diagnostics Markets 2Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans 2Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans 3Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans 4Texas A&M professor helps develop first high-temp spin-field-effect transistor 2Texas A&M professor helps develop first high-temp spin-field-effect transistor 3
(Date:4/20/2015)... , April 20, 2015 ...   Glenbeigh Records Management (GRM), Ireland,s ... with Dubai Islamic Bank. Having built up an impressive track ... now a leading player within the records management sector in ... expects to double is GCC staffbase and employ a further ...
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... Biologists have identified plant enzymes that may help to ... to use water more efficiently. The finding could help ... gases. Plants take in the carbon dioxide they ... surface of leaves. But for each molecule of the ...
... by Yale University researchers has used nanosensors to measure ... Their findings, which appear December 13 in the advanced ... simplify the way physicians test for biomarkers of cancer ... Mark Reed, Yale,s Harold Hodgkinson Professor of Engineering & ...
... 2009Researchers at The Scripps Research Institute have solved a ... ancient family of enzymes can have two completely distinct ... for understanding other molecules in the family, the research ... for combating diseases including cancer and macular degeneration. ...
Cached Biology News:Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Scripps Research scientists crack mystery of protein's dual function 2Scripps Research scientists crack mystery of protein's dual function 3
... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Phospho-FADD (Ser194) Antibody (Human Specific)...
Biology Products: